 Shanlee Davis
Concepts (179)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Klinefelter Syndrome | 13 | 2022 | 53 | 5.090 |
Why?
| | Turner Syndrome | 6 | 2023 | 51 | 3.480 |
Why?
| | Testosterone | 5 | 2022 | 357 | 1.470 |
Why?
| | Oxandrolone | 3 | 2018 | 8 | 1.350 |
Why?
| | Sex Chromosome Aberrations | 5 | 2023 | 55 | 1.090 |
Why?
| | Cardiovascular Diseases | 4 | 2022 | 1904 | 0.980 |
Why?
| | Anti-Mullerian Hormone | 2 | 2020 | 51 | 0.870 |
Why?
| | XYY Karyotype | 2 | 2020 | 15 | 0.860 |
Why?
| | Puberty | 3 | 2020 | 148 | 0.860 |
Why?
| | Testis | 3 | 2018 | 147 | 0.770 |
Why?
| | Monosomy | 1 | 2021 | 10 | 0.760 |
Why?
| | Disorders of Sex Development | 1 | 2021 | 37 | 0.730 |
Why?
| | Mitochondria, Muscle | 1 | 2021 | 100 | 0.720 |
Why?
| | Ovarian Reserve | 1 | 2020 | 13 | 0.720 |
Why?
| | Sex Chromosome Disorders of Sex Development | 1 | 2020 | 9 | 0.710 |
Why?
| | Sex Chromosome Disorders | 1 | 2020 | 14 | 0.710 |
Why?
| | Inhibins | 1 | 2020 | 46 | 0.710 |
Why?
| | Dyslipidemias | 1 | 2022 | 169 | 0.710 |
Why?
| | Primary Ovarian Insufficiency | 1 | 2020 | 30 | 0.700 |
Why?
| | Androgens | 2 | 2018 | 169 | 0.690 |
Why?
| | Metabolic Syndrome | 3 | 2020 | 399 | 0.670 |
Why?
| | Body Composition | 3 | 2020 | 679 | 0.650 |
Why?
| | Child | 22 | 2023 | 20014 | 0.620 |
Why?
| | Electronic Health Records | 2 | 2023 | 875 | 0.580 |
Why?
| | Body Height | 1 | 2017 | 191 | 0.520 |
Why?
| | Adipose Tissue | 1 | 2019 | 620 | 0.510 |
Why?
| | Infertility, Male | 1 | 2015 | 64 | 0.500 |
Why?
| | Child Development | 1 | 2019 | 426 | 0.500 |
Why?
| | Hypokalemia | 1 | 2014 | 31 | 0.480 |
Why?
| | Hypertension | 1 | 2022 | 1257 | 0.430 |
Why?
| | Phenotype | 5 | 2023 | 3153 | 0.430 |
Why?
| | Diabetic Ketoacidosis | 1 | 2014 | 174 | 0.410 |
Why?
| | Muscle, Skeletal | 1 | 2021 | 1568 | 0.400 |
Why?
| | Diabetes Mellitus | 1 | 2020 | 988 | 0.400 |
Why?
| | Adolescent | 15 | 2023 | 19411 | 0.380 |
Why?
| | Male | 23 | 2023 | 60792 | 0.370 |
Why?
| | Obesity | 2 | 2022 | 2805 | 0.370 |
Why?
| | Aneuploidy | 4 | 2023 | 87 | 0.360 |
Why?
| | Humans | 33 | 2023 | 125131 | 0.360 |
Why?
| | Case-Control Studies | 3 | 2021 | 3326 | 0.320 |
Why?
| | Estradiol | 2 | 2023 | 484 | 0.320 |
Why?
| | Mosaicism | 2 | 2021 | 66 | 0.310 |
Why?
| | Chromosomes, Human, X | 3 | 2023 | 61 | 0.310 |
Why?
| | Female | 18 | 2023 | 64889 | 0.300 |
Why?
| | Chromosomes, Human, Y | 2 | 2021 | 15 | 0.270 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 2010 | 377 | 0.270 |
Why?
| | Epilepsy | 1 | 2010 | 298 | 0.260 |
Why?
| | Blood Glucose | 1 | 2014 | 2008 | 0.250 |
Why?
| | Sex Chromosomes | 2 | 2023 | 49 | 0.250 |
Why?
| | Double-Blind Method | 3 | 2018 | 1725 | 0.240 |
Why?
| | Karyotype | 2 | 2023 | 12 | 0.240 |
Why?
| | Y Chromosome | 1 | 2023 | 7 | 0.230 |
Why?
| | Cross-Sectional Studies | 5 | 2023 | 4854 | 0.230 |
Why?
| | Child, Preschool | 11 | 2023 | 9938 | 0.230 |
Why?
| | Follow-Up Studies | 3 | 2019 | 4824 | 0.210 |
Why?
| | Azabicyclo Compounds | 1 | 2022 | 5 | 0.200 |
Why?
| | Body Mass Index | 2 | 2020 | 2174 | 0.200 |
Why?
| | Oxadiazoles | 1 | 2022 | 33 | 0.200 |
Why?
| | Receptors, Corticotropin-Releasing Hormone | 1 | 2022 | 33 | 0.200 |
Why?
| | Adrenal Hyperplasia, Congenital | 1 | 2022 | 29 | 0.200 |
Why?
| | Phosphocreatine | 1 | 2021 | 38 | 0.200 |
Why?
| | Adenosine Diphosphate | 1 | 2021 | 90 | 0.190 |
Why?
| | Genitalia | 1 | 2021 | 29 | 0.190 |
Why?
| | Gonadotropins | 1 | 2020 | 37 | 0.180 |
Why?
| | Prognosis | 2 | 2019 | 3616 | 0.180 |
Why?
| | Waist Circumference | 1 | 2020 | 130 | 0.170 |
Why?
| | Magnetoencephalography | 1 | 2020 | 104 | 0.170 |
Why?
| | Hypogonadism | 1 | 2020 | 77 | 0.170 |
Why?
| | Trisomy | 1 | 2020 | 70 | 0.170 |
Why?
| | Developmental Disabilities | 2 | 2016 | 266 | 0.170 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2021 | 325 | 0.170 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2023 | 256 | 0.170 |
Why?
| | Genetic Association Studies | 1 | 2021 | 391 | 0.170 |
Why?
| | Inservice Training | 1 | 2020 | 113 | 0.170 |
Why?
| | Young Adult | 7 | 2023 | 11384 | 0.170 |
Why?
| | Focal Dermal Hypoplasia | 1 | 2019 | 6 | 0.160 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2021 | 532 | 0.160 |
Why?
| | Adenosine Triphosphate | 1 | 2021 | 459 | 0.160 |
Why?
| | Failure to Thrive | 1 | 2019 | 32 | 0.160 |
Why?
| | Testicular Hormones | 1 | 2018 | 9 | 0.160 |
Why?
| | Motor Skills Disorders | 1 | 2018 | 24 | 0.160 |
Why?
| | Face | 1 | 2020 | 174 | 0.160 |
Why?
| | Hypothalamo-Hypophyseal System | 1 | 2020 | 204 | 0.160 |
Why?
| | Growth Disorders | 1 | 2019 | 87 | 0.160 |
Why?
| | Mentors | 1 | 2020 | 177 | 0.160 |
Why?
| | Mentoring | 1 | 2020 | 107 | 0.150 |
Why?
| | Interprofessional Relations | 1 | 2020 | 282 | 0.150 |
Why?
| | Overweight | 1 | 2022 | 520 | 0.150 |
Why?
| | Triglycerides | 1 | 2020 | 551 | 0.150 |
Why?
| | Patient Acceptance of Health Care | 1 | 2023 | 716 | 0.150 |
Why?
| | Eosinophilic Esophagitis | 1 | 2021 | 308 | 0.140 |
Why?
| | Infant | 5 | 2021 | 8625 | 0.140 |
Why?
| | Infant, Newborn | 3 | 2020 | 5456 | 0.140 |
Why?
| | Cohort Studies | 3 | 2020 | 5348 | 0.140 |
Why?
| | X Chromosome Inactivation | 1 | 2016 | 23 | 0.140 |
Why?
| | Speech Disorders | 1 | 2016 | 36 | 0.140 |
Why?
| | Imaging, Three-Dimensional | 1 | 2020 | 554 | 0.130 |
Why?
| | Truth Disclosure | 1 | 2016 | 42 | 0.130 |
Why?
| | Language Development Disorders | 1 | 2016 | 43 | 0.130 |
Why?
| | Delivery of Health Care | 1 | 2023 | 925 | 0.130 |
Why?
| | Algorithms | 1 | 2023 | 1618 | 0.130 |
Why?
| | Risk | 1 | 2019 | 896 | 0.130 |
Why?
| | Genetic Counseling | 1 | 2016 | 69 | 0.130 |
Why?
| | Transcription Factors | 1 | 2023 | 1604 | 0.130 |
Why?
| | Mitochondria | 1 | 2021 | 823 | 0.130 |
Why?
| | Registries | 1 | 2023 | 2050 | 0.120 |
Why?
| | Body Weight | 1 | 2019 | 959 | 0.120 |
Why?
| | Child Behavior Disorders | 1 | 2016 | 138 | 0.120 |
Why?
| | Child Behavior | 1 | 2017 | 238 | 0.120 |
Why?
| | Adult | 7 | 2022 | 33167 | 0.120 |
Why?
| | Muscle Strength | 1 | 2017 | 294 | 0.120 |
Why?
| | Potassium | 1 | 2014 | 154 | 0.120 |
Why?
| | Sex Factors | 1 | 2019 | 1901 | 0.110 |
Why?
| | Severity of Illness Index | 3 | 2017 | 2848 | 0.110 |
Why?
| | Insulin Resistance | 1 | 2021 | 1214 | 0.110 |
Why?
| | Polymorphism, Genetic | 1 | 2016 | 669 | 0.110 |
Why?
| | Genetic Predisposition to Disease | 1 | 2021 | 2382 | 0.100 |
Why?
| | Longitudinal Studies | 1 | 2019 | 2669 | 0.100 |
Why?
| | Quality of Life | 1 | 2023 | 2580 | 0.100 |
Why?
| | Autism Spectrum Disorder | 1 | 2017 | 374 | 0.100 |
Why?
| | Hypoglycemia | 1 | 2016 | 413 | 0.100 |
Why?
| | Biomarkers | 2 | 2022 | 3736 | 0.090 |
Why?
| | Treatment Outcome | 3 | 2022 | 9790 | 0.090 |
Why?
| | Gene Expression Profiling | 1 | 2016 | 1642 | 0.080 |
Why?
| | Cognition | 1 | 2017 | 1069 | 0.080 |
Why?
| | Neoplasms | 1 | 2023 | 2340 | 0.080 |
Why?
| | Hypoglycemic Agents | 1 | 2016 | 1081 | 0.080 |
Why?
| | Quality Improvement | 1 | 2016 | 1020 | 0.080 |
Why?
| | Brain | 1 | 2020 | 2639 | 0.080 |
Why?
| | Hospitalization | 1 | 2016 | 1960 | 0.070 |
Why?
| | Abnormalities, Multiple | 1 | 2008 | 185 | 0.070 |
Why?
| | Insulin | 1 | 2016 | 2219 | 0.070 |
Why?
| | Prevalence | 2 | 2023 | 2488 | 0.070 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2019 | 2236 | 0.060 |
Why?
| | Syndrome | 2 | 2020 | 367 | 0.060 |
Why?
| | Sexual Development | 1 | 2023 | 21 | 0.050 |
Why?
| | Karyotyping | 1 | 2023 | 112 | 0.050 |
Why?
| | Menarche | 1 | 2023 | 51 | 0.050 |
Why?
| | 17-alpha-Hydroxyprogesterone | 1 | 2022 | 3 | 0.050 |
Why?
| | Androstenedione | 1 | 2022 | 10 | 0.050 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2022 | 154 | 0.050 |
Why?
| | Prenatal Diagnosis | 1 | 2022 | 173 | 0.050 |
Why?
| | Mental Disorders | 1 | 2008 | 976 | 0.040 |
Why?
| | Physicians, Women | 1 | 2020 | 55 | 0.040 |
Why?
| | Retrospective Studies | 3 | 2023 | 13708 | 0.040 |
Why?
| | Administration, Oral | 1 | 2022 | 785 | 0.040 |
Why?
| | Counseling | 1 | 2022 | 383 | 0.040 |
Why?
| | Morbidity | 1 | 2020 | 310 | 0.040 |
Why?
| | Genetic Testing | 1 | 2021 | 401 | 0.040 |
Why?
| | Peer Group | 1 | 2020 | 214 | 0.040 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2014 | 3471 | 0.040 |
Why?
| | Gene Expression | 1 | 2023 | 1528 | 0.040 |
Why?
| | Minority Groups | 1 | 2020 | 251 | 0.040 |
Why?
| | Career Choice | 1 | 2020 | 210 | 0.040 |
Why?
| | Health Status | 1 | 2023 | 794 | 0.040 |
Why?
| | Universities | 1 | 2020 | 368 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2022 | 2026 | 0.040 |
Why?
| | Diagnosis, Differential | 1 | 2021 | 1431 | 0.040 |
Why?
| | Mental Health | 1 | 2023 | 594 | 0.040 |
Why?
| | Social Media | 1 | 2020 | 164 | 0.040 |
Why?
| | Occupational Exposure | 1 | 2020 | 314 | 0.040 |
Why?
| | Disability Evaluation | 1 | 2018 | 290 | 0.040 |
Why?
| | Social Support | 1 | 2020 | 591 | 0.030 |
Why?
| | Societies, Medical | 1 | 2020 | 754 | 0.030 |
Why?
| | Tertiary Care Centers | 1 | 2016 | 137 | 0.030 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 360 | 0.030 |
Why?
| | Coronavirus Infections | 1 | 2020 | 347 | 0.030 |
Why?
| | Interpersonal Relations | 1 | 2017 | 366 | 0.030 |
Why?
| | Hospitals, Pediatric | 1 | 2016 | 517 | 0.030 |
Why?
| | Neuropsychological Tests | 1 | 2017 | 1084 | 0.030 |
Why?
| | Comorbidity | 1 | 2017 | 1635 | 0.020 |
Why?
| | Physicians | 1 | 2020 | 836 | 0.020 |
Why?
| | Pandemics | 1 | 2020 | 1434 | 0.020 |
Why?
| | Pregnancy | 1 | 2022 | 5922 | 0.020 |
Why?
| | Anxiety | 1 | 2017 | 924 | 0.020 |
Why?
| | Depression | 1 | 2017 | 1236 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2016 | 1530 | 0.020 |
Why?
| | Middle Aged | 2 | 2022 | 29112 | 0.020 |
Why?
| | United States | 1 | 2020 | 13613 | 0.010 |
Why?
|
|
Davis's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|